Aldeyra Therapeutics Inc (ALDX)

• $4.09

  $4.21

  $4.15
  

  1.45%

  Downside

  Day's Volatility :2.85%

  Upside

  1.43%

  
• $1.42

  $8.38

  $4.15
  

  65.78%

  Downside

  52 Weeks Volatility :83.05%

  Upside

  50.48%

  

Returns

What analysts predicted

Upside of 122.89%

• Perceptive Advisors LLC

  14.46%

• Knoll Capital Management LP

  9.22%

• Vanguard Group Inc

  6.51%

• BlackRock Inc

  5.57%

• Kennedy Capital Management Inc

  2.22%

• Geode Capital Management, LLC

  1.73%

dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise